

Su Jin Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3399492/publications.pdf>

Version: 2024-02-01

203
papers

5,101
citations

126907

33
h-index

123424

61
g-index

203
all docs

203
docs citations

203
times ranked

9480
citing authors

#	ARTICLE	IF	CITATIONS
1	Postnatal regulation of B-1a cell development and survival by the CIC-PER2-BHLHE41 axis. <i>Cell Reports</i> , 2022, 38, 110386.	6.4	7
2	IOX1 activity as sepsis therapy and an antibiotic against multidrug-resistant bacteria. <i>Scientific Reports</i> , 2021, 11, 2942.	3.3	4
3	Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis. <i>Biochemical and Biophysical Research Communications</i> , 2021, 543, 1-7.	2.1	10
4	Comparison of bone single-photon emission computed tomography (SPECT)/CT and bone scintigraphy in assessing knee joints. <i>BMC Medical Imaging</i> , 2021, 21, 60.	2.7	5
5	Early-phase 18F-FP-CIT and 18F-flutemetamol PET were significantly correlated. <i>Scientific Reports</i> , 2021, 11, 12297.	3.3	5
6	Skeletal muscle mass at C3 may not be a strong predictor for skeletal muscle mass at L3 in sarcopenic patients with head and neck cancer. <i>PLoS ONE</i> , 2021, 16, e0254844.	2.5	12
7	IOX1 impedes host inflammation in imiquimod-triggered psoriasis. <i>Heliyon</i> , 2021, 7, e08433.	3.2	0
8	Primary Subcapsular Reflux as an Etiology of Subcapsular Renal Abscess. <i>Childhood Kidney Diseases</i> , 2021, 25, 133-139.	0.4	0
9	Homeostasis and regulation of autoreactive B cells. <i>Cellular and Molecular Immunology</i> , 2020, 17, 561-569.	10.5	18
10	Cell cycle synchronisation using thiazolidinediones affects cellular glucose metabolism and enhances the therapeutic effect of 2-deoxyglucose in colon cancer. <i>Scientific Reports</i> , 2020, 10, 4713.	3.3	4
11	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	7
12	Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2825.	4.1	11
13	The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 225-231.	2.0	4
14	Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody. <i>BMC Cancer</i> , 2019, 19, 805.	2.6	9
15	Gastrointestinal stromal tumour with CDKN2A deletions: a report of three cases. <i>Pathology</i> , 2019, 51, 537-539.	0.6	0
16	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. <i>Journal of Cancer</i> , 2019, 10, 3140-3144.	2.5	5
17	Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2019, 8, 6986-6994.	2.8	37
18	Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. <i>Translational Oncology</i> , 2019, 12, 597-601.	3.7	8

#	ARTICLE	IF	CITATIONS
19	A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer. <i>BMC Urology</i> , 2019, 19, 30.	1.4	5
20	The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2019, 10, 1611-1615.	2.5	7
21	PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data. <i>Lung Cancer</i> , 2019, 129, 41-47.	2.0	24
22	Can the basal serum thyroglobulin level be used to predict the recombinant human TSH-stimulated thyroglobulin level in differentiated patients with thyroid cancer?. <i>Medicine (United States)</i> , 2019, 98, e18437.	1.0	0
23	Anaplastic Oligodendroglioma Found as an Incidental Photopenic Lesion on 18F-FP-CIT PET/CT Image. <i>Clinical Nuclear Medicine</i> , 2019, 44, e168-e169.	1.3	1
24	Risk Factors for Indeterminate Response After Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, 714-718.	1.3	7
25	Intratumoral heterogeneity as measured using the tumor-stroma ratio and PET texture analyses in females with lung adenocarcinomas differs from that of males with lung adenocarcinomas or squamous cell carcinomas. <i>Medicine (United States)</i> , 2019, 98, e14876.	1.0	6
26	LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target. <i>Journal of Immunotherapy</i> , 2019, 42, 279-283.	2.4	11
27	A Case of Radioactive Iodine Uptake Found in Artificial Eye. <i>Clinical Nuclear Medicine</i> , 2019, 44, 317-318.	1.3	2
28	A Machine-Learning Approach Using PET-Based Radiomics to Predict the Histological Subtypes of Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, 956-960.	1.3	101
29	Clinicopathologic parameters associated with the FDG-avidity in staging of early gastric cancer using 18F-FDG PET. <i>Medicine (United States)</i> , 2019, 98, e16690.	1.0	4
30	Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. <i>PLoS ONE</i> , 2019, 14, e0210730.	2.5	64
31	18F-fluorodeoxyglucose positron emission tomography is correlated with the pathological necrosis and decreased microvessel density in lung adenocarcinomas. <i>Annals of Nuclear Medicine</i> , 2019, 33, 93-102.	2.2	7
32	Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 567-572.	2.6	44
33	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3104-3104.	1.6	2
34	A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. <i>Cancer Research and Treatment</i> , 2019, 51, 718-726.	3.0	10
35	Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols. <i>Cancer Research and Treatment</i> , 2019, 51, 876-885.	3.0	8
36	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 213-213.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Phase 1a study results investigating the safety and preliminary efficacy of ABLO01 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2019, 37, 3023-3023.	1.6	3
38	Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study. Cancer Research and Treatment, 2019, 51, 1269-1274.	3.0	4
39	Enhanced Expression and Functional Characterization of the Recombinant Putative Lysozyme-PMAP36 Fusion Protein. Molecules and Cells, 2019, 42, 262-269.	2.6	3
40	MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis. Molecular Cancer Therapeutics, 2018, 17, 838-848.	4.1	36
41	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. Clinical Colorectal Cancer, 2018, 17, 140-146.	2.3	17
42	c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. Clinical Colorectal Cancer, 2018, 17, 165-169.	2.3	71
43	The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. Translational Oncology, 2018, 11, 353-357.	3.7	8
44	Clinical benefit and residual kidney function of en bloc nephrectomy for perirenal retroperitoneal sarcoma. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e465-e471.	1.1	4
45	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. Journal of Gastric Cancer, 2018, 18, 348.	2.5	12
46	Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma. BMC Urology, 2018, 18, 68.	1.4	18
47	Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. Radiotherapy and Oncology, 2018, 129, 306-312.	0.6	12
48	Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. Journal of Gynecologic Oncology, 2018, 29, e3.	2.2	13
49	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nature Medicine, 2018, 24, 1449-1458.	30.7	1,071
50	Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. Journal of Cancer, 2018, 9, 2910-2915.	2.5	6
51	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. Journal of Clinical Oncology, 2018, 36, e14501-e14501.	1.6	1
52	Associations Between PET Textural Features and GLUT1 Expression, and the Prognostic Significance of Textural Features in Lung Adenocarcinoma. Anticancer Research, 2018, 38, 1067-1071.	1.1	11
53	Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. Cancer Research and Treatment, 2018, 50, 488-494.	3.0	28
54	VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.. Journal of Clinical Oncology, 2018, 36, e24234-e24234.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Detection of targetable fusions using FusionPlex in oncology patients.. Journal of Clinical Oncology, 2018, 36, e24238-e24238.	1.6	0
56	Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 61-67.	1.1	18
57	Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). Cancer, 2017, 123, 1958-1964.	4.1	44
58	Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters. Lung Cancer, 2017, 104, 31-37.	2.0	54
59	A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. Journal of Geriatric Oncology, 2017, 8, 170-175.	1.0	39
60	Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma. Apmis, 2017, 125, 223-229.	2.0	15
61	Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. Investigational New Drugs, 2017, 35, 782-790.	2.6	22
62	Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists. Expert Opinion on Emerging Drugs, 2017, 22, 191-200.	2.4	3
63	Neogargarooligosaccharides prevent septic shock by modulating A20-and cyclooxygenase-2-mediated interleukin-10 secretion in a septic-shock mouse model. Biochemical and Biophysical Research Communications, 2017, 486, 998-1004.	2.1	19
64	Intratumoural heterogeneity measured using FDG PET and MRI is associated with tumour-stroma ratio and clinical outcome in head and neck squamous cell carcinoma. Clinical Radiology, 2017, 72, 482-489.	1.1	25
65	A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer. BMC Urology, 2017, 17, 63.	1.4	7
66	Radiolabeled Anti-Adenosine Triphosphate Synthase Monoclonal Antibody as a Theragnostic Agent Targeting Angiogenesis. Molecular Imaging, 2017, 16, 153601211773739.	1.4	6
67	Prognostic significance of lactate dehydrogenase B according to histologic type of non-small-cell lung cancer and its association with serum lactate dehydrogenase. Pathology Research and Practice, 2017, 213, 1134-1138.	2.3	20
68	Clinical usefulness of F-18 FDG PET in lymphoepithelioma-like gastric carcinoma. European Journal of Radiology, 2017, 94, 160-166.	2.6	7
69	Prognostic value of preoperative total psoas muscle area on long-term outcome in surgically treated oesophageal cancer patients. Interactive Cardiovascular and Thoracic Surgery, 2017, 24, 13-19.	1.1	20
70	Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis. Medicine (United States), 2017, 96, e8985.	1.0	11
71	An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients. Journal of Cancer, 2017, 8, 730-736.	2.5	1
72	Prognostic Significance of EDIL3 Expression and Correlation with Mesenchymal Phenotype and Microvessel Density in Lung Adenocarcinoma. Scientific Reports, 2017, 7, 8649.	3.3	28

#	ARTICLE	IF	CITATIONS
73	Serosal Cavities Contain Two Populations of Innate-like integrin $\alpha 4^{\text{high}}\text{CD4}^{\text{+}}\text{T}$ Cells, Integrin $\alpha 4^{\text{low}}\text{CD4}^{\text{+}}\text{T}$ Cells, and $\alpha 4^{\text{low}}\text{CD4}^{\text{+}}\text{T}$ Cells. <i>Immune Network</i> , 2017, 17, 392.	3.6	4
74	Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer. <i>Oncotarget</i> , 2017, 8, 11094-11104.	1.8	21
75	Postoperative change of the psoas muscle area as a predictor of survival in surgically treated esophageal cancer patients. <i>Journal of Thoracic Disease</i> , 2017, 9, 355-361.	1.4	17
76	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. <i>Oncotarget</i> , 2017, 8, 3237-3245.	1.8	20
77	MerTK is a novel therapeutic target in gastric cancer. <i>Oncotarget</i> , 2017, 8, 96656-96667.	1.8	23
78	Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. <i>Cancer Research and Treatment</i> , 2017, 49, 350-357.	3.0	23
79	Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14622-e14622.	1.6	0
80	The impact of pathologic differentiation (well/ poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15686-e15686.	1.6	0
81	Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. <i>Journal of Cancer</i> , 2016, 7, 1044-1048.	2.5	17
82	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. <i>Journal of Gastric Cancer</i> , 2016, 16, 105.	2.5	34
83	The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. <i>Journal of Cancer</i> , 2016, 7, 484-489.	2.5	106
84	Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma. <i>Translational Oncology</i> , 2016, 9, 557-564.	3.7	16
85	Clinical significance of post-treatment ^{18}F -fluorodeoxyglucose uptake in cervical lymph nodes in patients with diffuse large B-cell lymphoma. <i>European Radiology</i> , 2016, 26, 4632-4639.	4.5	14
86	BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells. <i>Translational Oncology</i> , 2016, 9, 197-202.	3.7	10
87	The Highest Metabolic Activity on FDG PET Is Associated With Overall Survival in Limited-Stage Small-Cell Lung Cancer. <i>Medicine (United States)</i> , 2016, 95, e2772.	1.0	18
88	The prognostic value of total lesion glycolysis via ^{18}F -fluorodeoxyglucose PET-CT in surgically treated esophageal squamous cell carcinoma. <i>Annals of Nuclear Medicine</i> , 2016, 30, 81-88.	2.2	15
89	A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. <i>BMC Urology</i> , 2016, 16, 46.	1.4	14
90	Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma. <i>Translational Oncology</i> , 2016, 9, 466-471.	3.7	13

#	ARTICLE	IF	CITATIONS
91	A Korean single-center, real-world, retrospective study of first-line weekly paclitaxel in patients with metastatic angiosarcoma. <i>Clinical Sarcoma Research</i> , 2016, 6, 8.	2.3	10
92	Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 40-45.	1.3	9
93	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1231-1237.	2.5	11
94	Comparison of Diagnostic Performance Between Visual and Quantitative Assessment of Bone Scintigraphy Results in Patients With Painful Temporomandibular Disorder. <i>Medicine (United States)</i> , 2016, 95, e2485.	1.0	5
95	Troglitazone Stimulates Cancer Cell Uptake of ¹⁸ F-FDG by Suppressing Mitochondrial Respiration and Augments Sensitivity to Glucose Restriction. <i>Journal of Nuclear Medicine</i> , 2016, 57, 129-135.	5.0	5
96	Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6090-6090.	1.6	3
97	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. <i>Oncotarget</i> , 2016, 7, 24088-24096.	1.8	15
98	Enhancing the Therapeutic Efficacy of 2-Deoxyglucose in Breast Cancer Cells Using Cell-cycle Synchronization. <i>Anticancer Research</i> , 2016, 36, 5975-5980.	1.1	8
99	The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancer Research and Treatment</i> , 2016, 48, 153-161.	3.0	11
100	A retrospective feasibility analysis of biweekly reduced dose docetaxel in Korean patients with castration-resistant, metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e638-e638.	1.6	0
101	Adjuvant chemotherapy with or without concurrent radiotherapy in stage IB patients with gastric cancer: Subgroup analysis of the adjuvant chemoradiotherapy in stomach tumors (ARTIST) phase III trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 95-95.	1.6	0
102	Tuberous sclerosis complex 2 (TSC2) expression in hepatocellular carcinoma to predict responses to mTOR inhibitor.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15628-e15628.	1.6	0
103	The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institution.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4091-4091.	1.6	0
104	The impact of cetuximab plus AKT- or mTOR- inhibitor in patient-derived colon cancer cell model with RAS wild type and PIK3CA mutation.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15153-e15153.	1.6	0
105	Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer. <i>Medicine (United States)</i> , 2015, 94, e2063.	1.0	17
106	The Correlations Between MRI Perfusion, Diffusion Parameters, and 18F-FDG PET Metabolic Parameters in Primary Head-and-Neck Cancer. <i>Medicine (United States)</i> , 2015, 94, e2141.	1.0	31
107	The Utility of Segmental Analysis in Cardiac I-123 MIBG SPECT in Parkinson's Disease. <i>Nuclear Medicine and Molecular Imaging</i> , 2015, 49, 298-302.	1.0	5
108	Prediction of occult lymph node metastasis using volume-based PET parameters in small-sized peripheral non-small cell lung cancer. <i>Cancer Imaging</i> , 2015, 15, 21.	2.8	43

#	ARTICLE	IF	CITATIONS
109	Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring <i>KIT</i> Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). <i>Oncologist</i> , 2015, 20, 1312-1319.	3.7	70
110	Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. <i>BMC Cancer</i> , 2015, 15, 693.	2.6	23
111	Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. <i>BMC Cancer</i> , 2015, 15, 747.	2.6	10
112	Physiologic Facial Muscle Uptake on 18F-FDG PET/CT by Chewing-Like Habitual Movement in Patient With Sjögren Syndrome. <i>Clinical Nuclear Medicine</i> , 2015, 40, 268-269.	1.3	6
113	Circulating Tumor Cells are Predictive of Poor Response to Chemotherapy in Metastatic gastric cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 382-386.	1.8	25
114	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. <i>Oncotarget</i> , 2015, 6, 28211-28222.	1.8	57
115	Single Pulmonary Langerhans Cell Histiocytosis Mimicking Metastasis in Lung Cancer: Imaging with 18F-FDG PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2015, 49, 243-245.	1.0	2
116	Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea. <i>Breast</i> , 2015, 24, 213-217.	2.2	23
117	Correlation Between F-18 Fluorodeoxyglucose Positron Emission Tomography Metabolic Parameters and Dynamic Contrast-Enhanced MRI-Derived Perfusion Data in Patients with Invasive Ductal Breast Carcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 3866-3872.	1.5	18
118	Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. <i>BMC Cancer</i> , 2015, 15, 530.	2.6	17
119	Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. <i>BMC Cancer</i> , 2015, 15, 154.	2.6	58
120	Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. <i>Lung Cancer</i> , 2015, 90, 261-266.	2.0	4
121	Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, e287-e292.	2.4	10
122	Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 2522-2522.	1.6	2
123	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. <i>Oncotarget</i> , 2015, 6, 25619-25630.	1.8	48
124	PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA. <i>Oncotarget</i> , 2015, 6, 40026-40035.	1.8	15
125	NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. <i>Oncotarget</i> , 2015, 6, 39028-39035.	1.8	53
126	Salivary gland scintigraphy in Sjögren's syndrome. <i>Nuklearmedizin - Nuclear Medicine</i> , 2014, 53, 139-145.	0.7	18

#	ARTICLE	IF	CITATIONS
127	The Clinical Impacts of Apparent Embolic Event and the Predictors of In-Hospital Mortality in Patients with Infective Endocarditis. <i>Journal of Korean Medical Science</i> , 2014, 29, 1646.	2.5	2
128	Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI. <i>Nuklearmedizin - NuclearMedicine</i> , 2014, 53, 89-94.	0.7	41
129	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent <i>In Vitro</i> Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2527-2536.	4.1	34
130	Isolated Splenic Metastasis of Ovarian Cancer Detected With 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, 349-351.	1.3	6
131	Oxidized Low-Density Lipoprotein Stimulates Macrophage ¹⁸ F-FDG Uptake via Hypoxia-Inducible Factor-1 α Activation Through Nox2-Dependent Reactive Oxygen Species Generation. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1699-1705.	5.0	63
132	Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma. <i>Clinical Sarcoma Research</i> , 2014, 4, 13.	2.3	28
133	Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients. <i>Acta Haematologica</i> , 2014, 131, 193-199.	1.4	23
134	Incidentally Detected Juvenile-Pattern Bone Scintigraphy in a Young Man with Kallmann's Syndrome. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 247-248.	1.0	0
135	DCEP for relapsed or refractory multiple myeloma after therapy with novel agents. <i>Annals of Hematology</i> , 2014, 93, 99-105.	1.8	29
136	Prognostic significance of the intratumoral heterogeneity of ¹⁸ F-FDG uptake in oral cavity cancer. <i>Journal of Surgical Oncology</i> , 2014, 110, 702-706.	1.7	38
137	Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1063-1070.	2.3	18
138	Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1217-1225.	2.3	32
139	Significance of Salivary Gland Radioiodine Retention on Post-ablation ¹³¹ I Scintigraphy as a Predictor of Salivary Gland Dysfunction in Patients with Differentiated Thyroid Carcinoma. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 203-211.	1.0	11
140	Carotid Artery FDG Uptake May Serve as a Biomarker for Cardiovascular Risk Stratification in Asymptomatic Adults. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 196-202.	1.0	8
141	Natural history of untreated patients who had metastatic biliary tract cancer (BTC) with good performance status (PS).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15106-e15106.	1.6	0
142	Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. <i>Anticancer Research</i> , 2014, 34, 6585-91.	1.1	2
143	Usefulness of 18F-fluoride PET/CT in Breast Cancer Patients with Osteosclerotic Bone Metastases. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 27-35.	1.0	33
144	Symptomatic late-onset sialadenitis after radioiodine therapy in thyroid cancer. <i>Annals of Nuclear Medicine</i> , 2013, 27, 386-391.	2.2	33

#	ARTICLE	IF	CITATIONS
145	Inclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL). <i>International Journal of Hematology</i> , 2013, 97, 388-396.	1.6	6
146	Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes. <i>SpringerPlus</i> , 2013, 2, 136.	1.2	18
147	Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. <i>Investigational New Drugs</i> , 2013, 31, 1580-1586.	2.6	33
148	Symptomatic brain involvement as the initial manifestation of neuromyelitis optica. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 938-942.	1.5	9
149	Gastric cancer (GC) patients with hedgehog pathway activation: PTCH1 and GLI2 as independent prognostic factors. <i>Targeted Oncology</i> , 2013, 8, 271-280.	3.6	25
150	Identification of <i>ROS1</i> rearrangement in gastric adenocarcinoma. <i>Cancer</i> , 2013, 119, 1627-1635.	4.1	108
151	Incidental Focal Uptake in Oropharynx Due to Lingual Thyroid on Diagnostic ¹³¹ I Whole-Body Scan After Total Thyroidectomy. <i>Clinical Nuclear Medicine</i> , 2013, 38, 646-648.	1.3	2
152	Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma. <i>Melanoma Research</i> , 2013, 23, 147-151.	1.2	34
153	Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington's Disease: A Possible		

#	ARTICLE	IF	CITATIONS
163	A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. <i>Anticancer Research</i> , 2013, 33, 5179-86.	1.1	42
164	Apparent Relative Hypermetabolism of Selective Brain Areas in Huntington Disease and Importance of Reference Region for Analysis. <i>Clinical Nuclear Medicine</i> , 2012, 37, 663-668.	1.3	12
165	Primary Malignant Fibrous Histiocytoma in Mediastinum: Imaging with 18F-FDG PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2012, 46, 304-307.	1.0	9
166	ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis. <i>Lung Cancer</i> , 2012, 76, 253-254.	2.0	26
167	Unique perception of clinical trials by Korean cancer patients. <i>BMC Cancer</i> , 2012, 12, 594.	2.6	21
168	Prognostic Value of Volume-Based ¹⁸ F-Fluorodeoxyglucose PET/CT Parameters in Patients with Clinically Node-Negative Oral Tongue Squamous Cell Carcinoma. <i>Korean Journal of Radiology</i> , 2012, 13, 752.	3.4	48
169	Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 1540-1547.	2.6	14
170	Resting cerebral glucose metabolism and perfusion patterns in women with posttraumatic stress disorder related to sexual assault. <i>Psychiatry Research - Neuroimaging</i> , 2012, 201, 214-217.	1.8	22
171	Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. <i>The Korean Journal of Hepatology</i> , 2012, 18, 48.	1.5	34
172	A prospective, phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors. <i>Journal of Clinical Oncology</i> , 2012, 30, 7104-7104.	1.6	0
173	Non Malignant Late Complications After Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT); Korean Experience. <i>Blood</i> , 2012, 120, 4462-4462.	1.4	0
174	Correlation Between Unidentified Bright Objects on Brain Magnetic Resonance Imaging (MRI) and Cerebral Glucose Metabolism in Patients with Neurofibromatosis Type 1. <i>Journal of Genetic Medicine</i> , 2012, 9, 84-88.	0.2	0
175	Evaluation of Agreement between 64-slice Computed Tomography Angiography and 201-Tl Single Photon Emission Computed Tomography-myocardial Perfusion Imaging in the Diagnosis of Significant Coronary Artery Disease. <i>Journal of the Korean Society of Radiology</i> , 2011, 64, 541.	0.2	0
176	Incidental Multiple Focal Uptakes of Tc-99m MDP in Both Lungs Without Lung Parenchymal Abnormality. <i>Clinical Nuclear Medicine</i> , 2011, 36, 221-223.	1.3	4
177	Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 743-751.	2.3	27
178	Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 255-262.	2.3	31
179	Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy. <i>Medical Oncology</i> , 2011, 28, 291-294.	2.5	5
180	Clinical Significance of Diffuse 18F-FDG Uptake in Residual Thyroid Gland after Unilateral Thyroid Lobectomy. <i>Nuclear Medicine and Molecular Imaging</i> , 2011, 45, 197-202.	1.0	1

#	ARTICLE	IF	CITATIONS
181	Clinical presentation of carcinoma of unknown primary: 14 years of experience. <i>Tumor Biology</i> , 2011, 32, 45-51.	1.8	4
182	Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2011, 86, 346-350.	4.1	24
183	Analysis of Prognostic Factors of Pediatric-Type Sarcomas in Adult Patients. <i>Oncology</i> , 2011, 80, 21-28.	1.9	9
184	Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer. <i>Cancer Research and Treatment</i> , 2011, 43, 89-95.	3.0	79
185	Abstract B38: Troglitazone enhances breast cancer cell 18F-FDG uptake and intracellular lactic acid accumulation through PPAR-independent activation of the MAPK pathway.. , 2011, , .		0
186	Prognostic Value of Metabolic Tumor Volume Measured by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Esophageal Carcinoma. <i>Annals of Surgical Oncology</i> , 2010, 17, 115-122.	1.5	194
187	Survival benefit from ovarian metastasectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 229-235.	2.3	49
188	Extrasosseous osteosarcoma: Single institutional experience in Korea. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 126-129.	1.1	20
189	Multicenter Retrospective Study on the Development of Peripheral Lymphocytosis During Second-Line Dasatinib Therapy for Chronic Myeloid Leukemia. <i>Blood</i> , 2010, 116, 2275-2275.	1.4	1
190	Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. <i>International Journal of Cancer</i> , 2009, 124, 1457-1462.	5.1	69
191	Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. <i>Cancer</i> , 2009, 115, 1518-1530.	4.1	20
192	Atypical basal ganglia germinoma presenting as cerebral hemiatrophy: diagnosis and follow-up with 11C-methionine positron emission tomography. <i>Child's Nervous System</i> , 2009, 25, 29-37.	1.1	27
193	Rituximab-induced acute thrombocytopenia: a case report and review of the literature. <i>Medical Oncology</i> , 2009, 26, 45-48.	2.5	28
194	Variation in FDG uptake on PET in patients with radiation-induced pelvic insufficiency fractures: a review of 10 cases. <i>Annals of Nuclear Medicine</i> , 2009, 23, 511-516.	2.2	9
195	Modified Transobturator Tape (Canal Transobturator Tape) Surgery for Female Stress Urinary Incontinence. <i>Journal of Urology</i> , 2009, 181, 2616-2621.	0.4	11
196	Myocardial perfusion defects and coronary risk factors in symptomatic and asymptomatic elderly women. <i>International Journal of Cardiovascular Imaging</i> , 2008, 24, 277-281.	1.5	8
197	Comparison of Uptake Characteristics and Prognostic Value of ²⁰¹ Tl and ¹⁸ F-FDG in Esophageal Cancer. <i>World Journal of Surgery</i> , 2008, 32, 69-75.	1.6	6
198	Potential value of radionuclide cisternography in diagnosis and management planning of spontaneous intracranial hypotension. <i>Clinical Neurology and Neurosurgery</i> , 2008, 110, 657-661.	1.4	37

#	ARTICLE	IF	CITATIONS
199	Reversal of Vascular ¹⁸ F-FDG Uptake with Plasma High-Density Lipoprotein Elevation by Atherogenic Risk Reduction. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1277-1282.	5.0	108
200	Neutrophil Counts Could Predict the Response to Immunosuppressive Treatment with Antithymocyte Globulin and Cyclosporine in the Patients with Severe Aplastic Anemia. <i>Blood</i> , 2008, 112, 4109-4109.	1.4	8
201	BCL2 Gene Polymorphism Could Predict the Treatment Outcomes in Patients with De Novo Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 3973-3973.	1.4	0
202	Localization of Dystonic Muscles with ¹⁸ F-FDG PET/CT in Idiopathic Cervical Dystonia. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1790-1795.	5.0	40
203	Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. <i>Journal of Gynecologic Oncology</i> , 0, 29, .	2.2	0